SCHEMBL6845136

SCHEMBL6845136

CC(=O)Nc1cccc(-c2nc(-c3ccnc(NC(C)=O)c3)sc2-c2ncc[nH]2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.49
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
KDM4E B2RXH2 5/20 0.46
MAPT P10636 5/20 0.46
ALDH1A1 P00352 5/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
POLB P06746 2/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
JAK3 P52333 1/20 0.45
MELK Q14680 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6842853 0.91 MAPK14 (0.61) MAPK14SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL952377 0.91 MAPK14 (0.48) MAPK14KDM4EMAPTALDH1A1EGFR
SCHEMBL6842883 0.90 MAPK14 (0.49) MAPK14EGFRPIK3C3
SCHEMBL6842823 0.90 MAPK14 (0.49) MAPK14SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL6845075 0.90 PIK3C3 (0.45) MAPK14SMN1; SMN2NPC1KDM4EMAPT
SCHEMBL16938026 0.88 ADORA1 (0.53) MAPK14SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL6842835 0.88 MAPK14 (0.51) MAPK14SMN1; SMN2ALDH1A1PIK3C3
SCHEMBL6842841 0.88 PIK3C3 (0.47) MAPK14PIK3C3
SCHEMBL16938039 0.86 MAPK14 (0.46) MAPK14PIP5K1CPIK3CAPIK3C3
SCHEMBL13256721 0.86 PIK3C3 (0.44) MAPK14PIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 MAPK14 102/4885SMN1; SMN2 3758/4885NPC1 458/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 MAPK14 899/4885SMN1; SMN2 3959/4885NPC1 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.